Aspen Neuroscience will put itself to the test in 2026. The San Diego biotech aims to enter Phase 3 with its lead cell therapy for Parkinson’s disease next year, CEO Damien McDevitt told Endpoints News …
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
